ALOX5 Expression and Pathomics Features Reveal New Insights Into Lung Adenocarcinoma Prognosis: Model Construction and Functional Validation.

Peihong Hu, Chun Huang, Xin Liu, Qiang Li, Run Xiang, Xu Liang

Abstract read

In one paragraph

Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

ALOX5 Expression and Pathomics Features Reveal New Insights Into Lung Adenocarcinoma Prognosis: Model Construction and Functional Validation.Human mutation · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Peihong HuDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, uestc.edu.cn.ORCID https://orcid.org/0000-0003-3748-2915

Chun HuangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China, uestc.edu.cn.

Xin LiuSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China, uestc.edu.cn.

Qiang LiDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China, uestc.edu.cn.

Run XiangDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China, uestc.edu.cn.ORCID https://orcid.org/0000-0002-2565-3783

Xu LiangDepartment of Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China, uestc.edu.cn.ORCID https://orcid.org/0009-0000-1795-8109

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Arachidonic acid 5-lipoxygenase (ALOX5) is a biomarker of lung adenocarcinoma (LUAD). This research seeks to establish a prognostic model for LUAD by examining ALOX5 expression. Methods: The Cancer Genome Atlas database provided the pathological images and transcriptome data. To determine the prognostic value of ALOX5, survival analysis and Cox regression (univariate and multivariate) were conducted, along with subgroup analysis and interaction tests. The OTSU algorithm and the PyRadiomics package were used to segment the pathological images of patients with LUAD and extract pathological features. The gradient-enhanced model algorithm was used to construct the pathological omics model. The prognostic value of pathomics mechanism analysis was confirmed using the pathomics score (PS) output from the model. Cell experiments were used to verify gene function. Results: A total of 327 samples and seven best pathological features were included in the analysis. In LUAD, elevated levels of ALOX5 and PS were associated with improved overall survival. The gradient boosting machine (GBM) pathomics model demonstrated strong predictive performance and clinical applicability, achieving an area under the curve (AUC) of 0.786 in the training set ( Conclusions: There was a strong link between ALOX5 expression levels and OS in LUAD patients. A pathomics-based model can effectively predict the expression level of ALOX5; as a result, LUAD patients' prognoses can be predicted.

Indexed as

Adenocarcinoma of LungArachidonate 5-LipoxygenaseBiomarkers, TumorGene Expression Regulation, NeoplasticLung NeoplasmsCell Line, TumorFemaleGene Expression ProfilingHumansMalePrognosisALOX5 protein, humanArachidonate 5-LipoxygenaseBiomarkers, Tumorarachidonic acid 5-lipoxygenaselung adenocarcinomapathological mechanismpathomicsprognosis prediction

Identifiers

PMID41809565

DOI10.1155/humu/3303601

PMCPMC12968730

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.